Immunotherapy is a new approach to cancer treatment and a specialty of physicians at Norton Children’s Cancer Institute, affiliated with the University of Louisville.
Board-certified and fellowship-trained geneticists, pediatric oncologists and other specialists work together to tailor immunotherapy treatments that can provide new and effective options.
Changes to our genes — especially those that control how cells grow and divide — cause cancer. Some of these genetic changes are inherited and some aren’t. Our genetic oncologists and hematologists are at the leading edge of identifying diagnostic methods and treatments based in genetics.
These cancer-causing genetic changes often lead to the appearance of novel proteins that are recognized by our immune cells as foreign. In cancer immunotherapy, the goal is to harness the ability of our immune cells to recognize these cancer-associated proteins and stimulate the immune system to reject or destroy tumors. Immunotherapies can either boost the immune system or train the immune system to attack cancer cells.
The Norton Children’s immunotherapy program focuses on combining immunotherapy with conventional cancer treatments. Chemotherapy will be used to remove the bulk of the malignant disease, and immunotherapy will be added to eliminate any residual cancer cells, which could stage a comeback and cause disease relapse if they are left untreated.
William T. Tse, M.D., has recently joined the Norton Cancer Institute team and University of Louisville Physicians from the Northwestern University Feinberg School of Medicine in Chicago, Illinois. In addition to groundbreaking research, Dr. Tse brings a clinical focus on using less toxic methods of stem cell transplants. He’s found success with reduced-intensity conditioning transplant for children with severe immune deficiency. Patients tend to tolerate the new approach better, effectively rebuilding their immune system and correcting underlying defects.
Dr. Tse currently is working with a team of clinicians and scientists from University of Louisville and Norton Cancer Institute to establish the laboratory capacity to produce clinical-grade immune cells derived from patients and engineered to recognize high-risk leukemia, neuroblastoma and brain tumor cells. Once these immune cells are infused back into the patients, they will find their targets and actively eliminate any residual leukemia and cancer cells. This exciting immunotherapy approach represents a new frontier in the fight against childhood cancer and leukemia, and the University of Louisville and Norton Cancer Institute are committed to making it a successful therapy for children in Kentucky.
Patients tend to tolerate the new approach better, effectively rebuilding their immune system and correcting underlying defects.
Available immunotherapy treatments
- Monoclonal antibodies
- Cellular therapies
- Granulocyte-macrophage colony-stimulating factor
Norton Children’s offers advanced pediatric cancer care
Before he was born, Schielar Skaggs’ parents, Terry and Melissa, worried about the life their son would have. Would he survive childbirth? If he did, would his life be short and filled with suffering and […]Read Full Story